Pfizer Receives FDA Approval for Retevmo in RET Fusion-Positive Thyroid Cancer

Pfizer today announced that the FDA has approved Retevmo (selpercatinib) for the treatment of adults and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory. In the Phase 1/2 LIBRETTO-001 trial, Retevmo demonstrated an overall response rate of 79% in patients with RET fusion-positive thyroid cancer. The median duration of response was 18.4 months. This approval provides patients with RET fusion-positive thyroid cancer a new targeted treatment option.